LENSAR, Inc. (Nasdaq: LNSR), a medical technology company specializing in advanced robotic laser solutions for cataract treatment, announced the termination of its merger agreement with Alcon Research, LLC. The decision, effective March 16, 2026, comes as both parties recognized that the necessary U.S. regulatory approvals required for the merger were unlikely to be obtained by the agreement's outside date of April 23, 2026. The Federal Trade Commission (FTC) had indicated its intention to challenge the acquisition, prompting LENSAR and Alcon to mutually agree that terminating the merger was in their best interests. As part of the termination agreement, LENSAR will retain a $10 million deposit previously made by Alcon. LENSAR's CEO, Nick Curtis, expressed disappointment over the merger's termination but reaffirmed the company's commitment to advancing cataract surgery technology through its ALLY Robotic Cataract Laser System. The company plans to report its fourth-quarter financial results and provide a strategic update on March 31, 2026, where further details on its future direction will be shared.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.